Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate

Affiliations

• ¹ Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
• ² Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
• ³ Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
• ⁴ Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.
• ⁵ UOC Clinica di Chirurgia Senologica, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Integrated Diagnostic Surgical Sciences, School of Medicine, University of Genova, Genoa, Italy.
• ⁶ Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Italy.
• ⁷ Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
• ⁸ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
• ⁹ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: matteo.lambertini@unige.it.